Myra Garrett SC

Ms Garrett is a partner in the firm’s corporate/M&A department and was previously the firm’s managing partner from 2008 to 2014.

The award recognises her exceptional leadership and enduring influence on the Irish M&A landscape.

With a practice spanning public and private M&A, IPOs, capital markets, and corporate governance, Ms Garrett has led on some of the most significant and complex transactions in the market.

These have included including the sale of Beacon Hospital to Macquarie Asset Management — the largest healthcare transaction in Ireland in 2024 — and advising Harvey Performance Company LLC on its acquisition of ATA Group.

She also advised on the largest global pharma deal of 2023, Amgen’s US$28.3 billion acquisition of Horizon Therapeutics.

Ms Garrett currently serves as vice co-chair of the International Bar Association’s Rule of Law Forum and is the immediate past chair of the IBA’s section on public and professional interest.

In these roles, she has championed initiatives promoting the rule of law, developing law firm leadership programmes and assessing the impact of AI on legal practice.

In October 2024, she was granted patents of precedence, conferring the title of senior counsel in reflection of her outstanding contributions to the legal profession both in Ireland and internationally.

Commenting on the award, Ms Garrett said: “It is a privilege to be recognised among such an inspiring group of women.

“I have been fortunate to work with wonderful, supportive clients and exceptional colleagues throughout my career and I share this award with them.”

William Fry managing partner Stephen Keogh added: “This award is well-deserved recognition of Myra’s exceptional career to date and the influence she has had on the M&A landscape in Ireland.

“Her leadership, integrity, and strategic insight have shaped many of the most significant deals in the Irish market year after year. It is a fitting tribute to a true M&A legal expert.”